Liestal, Basel-Country, Switzerland
Oshen Holdings SA is dedicated to investments in the better ageing space, with a focus on fostering innovation in healthcare, biotech, and medtech. As Managing Partner since January 2023, the team identifies and invests in drug and device development. Prior to Oshen, I spent several years as an advisor and Board Member on a number of start-ups and emerging life sciences companies, focused on early stage product development. From 2000 to 2018, I was the co-founder and CEO of Kuros Therapeutics and Kuros Biosurgery, which were subsequently to become Kuros Biosciences AG. Prior to that I spent many years as a pharma and medtech analyst.
Managing Partner advising a family office investing in the better ageing space
Advising and assisting companies in the medtech, biotech, pharmaceutical, life sciences and healthcare space.
Worked with Hemotune for several months on how to develop and position their product development activities, including preclinical, clinical and financing strategy, subsequently becoming Chairman of the Board. Hemotune is a medical device company based in Zürich. The company is a spin-off from ETH Zurich, incubated at the Wyss Zürich, to translate advanced magnetic blood purification into clinical practice.
Artiria Medical is developing cutting edge technologies to bring micromotion deep in brain arteries, enabling seamless navigation for stroke treatment.
Testmate Health is developing a self-test for the four common sexually transmitted diseases (STDs) that provides results in minutes from urine. The digitally-enabled kit allows users to be connected to a doctor for follow-up and guidance via a smartphone.